The city of Sacramento, California, currently has 5 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
02/18/2025
Locations: Option Care - Sacramento, Sacramento, California +1 locations
Conditions: Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
02/10/2025
Locations: Local Institution - 0209, Sacramento, California
Conditions: Alzheimer Disease, Early Onset
Senicapoc in Alzheimer's Disease
Recruiting
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Co... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
01/23/2025
Locations: University of California, Davis Alzheimer's Disease Center, Sacramento, California
Conditions: Mild Cognitive Impairment, Alzheimer Disease
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
01/22/2025
Locations: Clinical Trials Research, Sacramento, California
Conditions: Alzheimer's Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Recruiting
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
Gender:
All
Ages:
All
Trial Updated:
05/01/2024
Locations: Sutter Health, Sacramento, California
Conditions: Mild Cognitive Impairment, Alzheimer Disease